Fly News Breaks for March 6, 2015
OREX
Mar 6, 2015 | 13:54 EDT
BofA/Merrill reiterted its Buy rating and $13 price target on Orexigen and said it does not expect Contrave to be pulled from the market and chances of being fined are low. The firm said potential upside from not conducting a second study is likely off the table, but sees limited impact to Contrave marketability.
News For OREX From the Last 2 Days
There are no results for your query OREX